ILMU KESIHATAN Weblog

ILMU KESIHATAN UNTUK BANGSA MALAYSIA DAN INDONESIA

Apa itu penyakit Kencing Tikus(Pathogenic Leptospires)

Penyakit kencing tikus atau Leptospirosis (juga dikenali sebagai, penyakit/sindrom Weil, demam canicola, demam ladang tebu, demam 7-hari  merupakan penyakit berjangkit zoonosis yang berpunca daripada spirochaete dalam genus Leptospira yang menjejaskan manusia dan sejumlah besar haiwan, termasuk mamalia, burung, afimbia, dan reptilia. Penyakit ini pertama kali digambarkan oleh Adolf Weil pada tahun 1886 apabila dia melaporkan “penyakit jangkitan akut dengan bengkak spleen (“splenomegaly”), penyakit kuning dan nephritis”. Leptospira pertama kali dilihat pada 1907 dari hirisan buah pinggang bedah siasat. Pada 1908, Inada dan Ito pertama kali mengenal pasti ia sebagai organisma penyebab  dan pada 1916 menyedari kehadirannya pada tikus.

Sungguhpun diakui sebagai antara zoonosis paling biasa di dunia, leptospirosis merupakan jangkitan bakteria jarang berlaku pada manusia. Jangkitan biasanya dipindahkan kepada manusia apabila air yang dicemari dengan air kencing haiwan menyentuh bukaan pada kulit, mata, atau dengan selaput lendir. Di luar kawasan tropika, kes leptospirosis berlaku mengikut musim dan kebanyakannya berlaku sekitar bulan Ogos–September/Februari–March.

Punca

Leptospirosis disebabkan oleh bakteria spirochaete yang dikenali sebagai Leptospira yang sekurang-kurangnya terdapat dalam 5 serovar kepentingan di Amerika Syarikat dan Kanada menyebabkan penyakit pada anjing (Icterohaemorrhagiae, Canicola, Pomona, Grippotyphosa, dan Bratislava)[5]. Terdapat jangkitan jenis lain (yang jarang). Secara genetik organisma leptospira berlainan boleh dikenal pasti secara serologi dan sebaliknya. Dengan itu, pertelingkahan wujud berkenaan asas mengenal pasti jenis. Sistem serologi tradisi kelihatannya lebih berguna dari segi diagnostik dan epidemiologi pada masa ini (yang mungkin berubah dengan pembangunan lanjut dan perkembangan teknologi seperti PCR – polymerase chain reaction).

Leptospirosis disebarkan melalui kencing haiwan yang dijangkiti dan berjangkit selagi ia masih lembab. Sungguhpun tikus, dan mondok merupakan hos utama, sejumlah besar mamalia lain termasuk anjing, rusa, arnab, landak, lembu, biri-biri, rakoon, possum, skunk, dan mamalia laut tertentu mampu membawa dan menyebarkan penyakit sebagai hos kedua. Anjing mungkin menjilat kencing haiwan yang dijangkiti dari rumput atau tanah, atau minum dari lopak yang dijangkit. Terdapat laporan “anjing rumah” dijangkiti leptospirosis kelihatannya kerana menjilat kencing tikus yang dijangkiti yang memasuki rumah. Jenis habitat yang berkemungkinan membawa bacteria berjangkit adalah tebing sungai berlumpur, terusan, longkang, dan kawasan peliharaan ternakan berlumpur di mana terdapat laluan biasa bagi samaada mamalia liar atau ladang. Terdapat kaitan langsung antara jumlah air hujan dan kejadian leptospirosis, menjadikannya bermusim di kawasan serdahana dan sepanjang tahun di kawasan bercuaca tropika.

Leptospirosis turut disebarkan melalui air mani haiwan dijangkiti.Pekerja rumah penyembelihan boleh dijangkiti melalui sentuhan dengan cecair badan dan darah.

Manusia boleh dijangkiti melalui hubungan dengan air, makanan, atau tanah yang mengandungi kencing haiwan yang dijangkiti ini. Ini mungkin berlaku dengan menelan makanan atau air yang dicemari, atau melalui sentuhan luka pada kulit. Penyakit ini tidak diketahui berjangkit dari manusia ke manusia dan kes penyebaran bacteria pada mereka yang sedang sembuh amat jarang bagi manusia. Leptospirosis biasa berlaku dikalangan peminat sukan air di kawasan tertentu kerana lama berendam diketahui menggalakkan kemasukan bakteria. Peluncur dan pengayuh air berbuih (“whitewater”) adalah berisiko tinggi di kawasan yang diketahui mempunyai bacteria, dan boleh dijangkit dengan menelan air tercemar Leptospirosis, menyimbah air tercemar Leptospirosis pada mata atau hidung, atau atau luka terdedah kepada air yang dijangkiti. Pekerjaan berisiko termasuk veterinarian, pekerja penyembelihan, petani, pekerja kumbahan, dan mereka yang bekerja di rumah tinggal, pendayung juga kadang-kala diketahui turut dijangkiti penyakit tersebut.

Simptom

Jangkitan Leptospiral pada manusia menyebabkan sejumlah symptom, dan sesetengah mereka yang dijangkiti mungkin tidak menunjukkan sebarang symptom sama sekali. Leptospirosis merupakan penyakit dwifasa (“biphasic”) yang bermula dengan simptom seperti selsema (demam, sejuk, myalgia, sakit kepala yang kuat). Fasa pertama sembuh, dan pesakit tanpa symptom (“asymptomatic”) sehingga fasa kedua bermula. Ini berciri meningitis, kerosakan hati (menyebabkan demam kuning), dan kegagalan buah pinggang. Jangkitan ini sering kali salah diagnosis kerana symptom yang meluas. Ini mendorong kepada jumlah kes berdaftar yang jauh lebih rendah berbanding yang sebenarnya berlaku. Simptom leptospirosis termasuk demam tinggi, askit kepala yang teruk, sejuk, sakik otot, dan muntah-muntah, dan mungkin termasuk demam kuning, mata merah, sakit perut, cirit-birit, dan keradangan. Simptom bagi manusia hadir selepas 4–14 hari tempoh pengeraman.

Tempoh pengeraman (tempoh pendedahan kepada symptom pertama bagi haiwan antara 2 hingga 20 hari. Bagi anjing kerosakan hati dan buah pinggang merupakan paling biasa oleh leptospirosis. Vaskulitis boleh berlaku, menyebabkan lebam/edema dan berkemungkinan pembekuan dalam salur darah tersebar (disseminated intravascular coagulation -DIC). Myocarditis, pericarditis, meningitis, dan uveitis juga turutan yang mungkin.Leptospirosis perlu disyaki dan dimasukkan sebagai sebahagian diagnosis pembezaan sekiranaya mata putih bagi anjing kelihatan jaundice (walaupun sedikit kekuningan). Ketiadaan jaundice tidak menyingkirkan kemungkinan leptospirosis sepenuhnya, dan kehadirannya mungkin menunjukkan hepatitis atau pathologi hati lain dan bukannya leptospirosis. Muntah-muntah, demam, hilang selera makan, kurang kencing, kencing gelap atau perang luar biasa, dan lesu juga merupakan tanda-tanda penyakit.

Komplikasi

Komplikasi termasuk meningitis, kelesuan melampau, kehilangan pendengaran, masaalah pernafasan, azotemia, dan masaalah buah pinggan (“renal interstitial tubular necrosis”, yang menyebabkan kegagalan buah pinggang dan sering kali kegagalan hati (bentuk penyakit ini yang teruk dikenali sebagai Penyakit Weil, sunggupun ia turut dikenali sebagai Sindrom Weil). Masaalah kardiovaskular juga mungkin.

SUMBER DARI WIKIPEDIA

_______________________________________________________________________________________________________

Life cycle of pathogenic leptospires

The life cycle of pathogenic leptospires can very in terms of the host species, but usually follows the sequence below:-
Entry to a host

The bacteria enter a host via portals such as damaged skin, certain mucous membranes, the lungs and conjunctival membranes. They are not thought capable of penetrating undamaged skin except where it has been exposed to water and has swollen significantly. Transfer to the portal requires the bacteria to be enveloped in water and so normally involves direct contact with urine or water containing the bacteria in suspension. Entry via the lungs requires inhalation of aerosol droplets and not the bacteria alone. Leptospires cannot exist as spores or reactivate once dessicated in the natural environment.

Once within the host tissues, pathogenic strains can reproduce as they are optimised for metabolism at body temperatures. Their survival depends on the lack of an efective host immune response, but they do not seem to cause an inflammatory reaction and so in a host without adapted immunity the chances of being able to establish a positive growth curve are high. In virulent strains the bacteria are resistant to attack from the innate immune system and so can develop rapidly, until the adaptive system has a change to select and replicate a cognate antibody. Saphrophytes, and the pathogens that are less virulent, seem to be easily targeted by the innate immune system and so are eliminated.
Growth

Leptosires that survive entry and the immediate innate response will rapidly migrate to the bloodstream and lymphatic system, so spreading throughout the host body within a very short time. Avirulent strains are rapidly removed by the immune system, but the speed of spread is far higher than in other bacterial infections and a host can show leptospira within blood samples in a matter of minutes from exposure. Pathogenic bacteria reproduce by binary fission, so the colony increases exponentially, and the typical doubling time is 8 hours. The growth continues unchecked until the adaptive immune response develops or the host dies.

A strain is virulent if it is adapted to reproduce rapidly in-vivo and has resistance to the innate immune response. No fully-resistant strains exist, so the adaptive response is always able to select a cognate antibody given ehough time. Virulence is directly related to pathogenicity – the host suffers illness because of the sheer number of leptospires in their body, not to any specifically-developed killing mechanism employed by different strains.


Reservoir hosts

One of more species in the environment will maintain the bacteria as a viable population, via urinary shedding. Reservoir hosts are carrier-state species and so are usually not clinically ill, or have a sufficiently short natural life that the infection has no bearing on host populations. Rats are the main reservoir host but other rodents, marsupials and feral mammals are known to perform the function. Humans are not capable of becoming carrier-state and so are incidental to the bacterial life cycle. Reservoir hosts can cross-infect each other via urine or congenitally. Sexual transmission is known to occur in many species.
Non-carrier hosts

These are infected either directly from carrier-state hosts through contact with urine, or via the environment where urine from infected hosts has been able to remain viable in water or soil. Non-carrier hosts are a mistake in the bacterial ecosystem as for genetic dissemination the bacteria of course prefer a host that will survive for as long as possible and shed as many bacteria as possible – non-carrier hosts often die from their illness and tend to be less efficient urinary shedders while they are still alive. However leptospires cannot tell which hosts they are infecting, and so many species pay the price simply by being in the wrong place at the wrong time.
Colony transfer

Reservoir hosts for leptospirosis are often non-migratory, and even territorial. This means that leptospiral genetic diversity in a local area can remain static, and this local cultivation is one of the reasons for such a large number of serovars and their frequent localisation. However the acute infection of non-reservoir hosts that do cross territorial boundaries allows for bacterial transfer and the slow migration of serovars across continents. Since birds seem unable to carry leptospirosis the speed of spread is far smaller than with other infections (such as avian infuenza) and for isolated places such as islands the leptospiral diversity can be fixed, or on occasion the bacteria can be completely absent. Since leptospires reproduce via binary fission there is no DNA combination between serovars or the host and the development of new serovars via mutative virulence selection is slow.
Survival outside the host

Pathogenic leptospires will survive in many environments for an extended time, lasting months or years, so allowing reinfection of animal hosts. The environmental conditions for survival are quite narrow and so the bacteria tend not to be as significant a problem ex-vivo as other bacteria or viruses.
Virulence changes

Broadly, leptospires are of two types – saphrophytes living in freshwater and using organic material as a food supply but not requiring a host, and pathogens that require a host. The metaphysical reason that pathogens require a host is debatable, as of course the saphrophytes prove that the bacteria can do perfectly well without one, but spread is enhanced by hitching a ride within a host animal, and pathogens have clearly evolved because of a nett benefit to their mode of operation.

In the past it was believed that leptospires ‘switched’ from one form into another, depending on where they found themselves. Saphrophytes entering a host’s tissues became pathogenic, then when excreted back into water they converted to saphrophytes again. This is known not to be true, but there is an important blurring of the line and a conversion process at play in other areas.

Firstly, saphrophytes can enter the body of a host just the same as pathogens, but are unable to exploit the conditions and reproduce rapidly. As such they are removed by the innate immune system within a few minutes and cause no long-term illness – however they can trigger an adaptive immune response and this is believed to be the reason that many aquatic species are immune to pathogenic infection – such as fish and amphibians. Many such species will show antibodies to saphrophyte-sourced antigens that are also cognate with antigens from pathogens.

Secondly, a pathogenic baterium that is cultured outside a host will gradually lose virulence, as genetic mutations alter the colony. Passing the culture through a host will select out the most virulent individuals, using the host’s immune system as a filter, and this is used to preserve and concentrate lab samples. In the natural environment the same process occurs and so a colony of pathogenic bacteria in a body of water will gradually lose their ability to cause disease.


Persistent human leptospirosis – guide for the public

Persistent infection is a situation where the patient has recovered from an acute illness, but shows some long-term health effects caused by the bacteria remaining in isolated areas of the body, long after the immune system has removed them from the bloodstream and general tissues. It is different from a carrier state as the patient is not infectious to others, but persistent human leptospirosis (PHL) is far more common than previously thought.

These long-term issues are not only a factor of leptospirosis – other infections from bacteria in the same order, such as Lyme disease, often show health problems for several years after recovery.
Symptoms of PHL

Symptoms vary a great deal between patients, with some being almost incapacitated and others noticing nothing. The reported symptoms are listed below, with the most common first:-

1. Depression, from mild personality changes to quite severe clinical disorders and suicides.
2. Fatigue, often quite pronounced and debilitating
3. Headaches, resembling migraines but not always particularly severe.
4. Eye pain, with or without any inflammation, sometimes with vision disturbances.
5. Psychological changes, including mood swings, short tempers, rarely OCD.
6. PIEM, parainfectious encephalomyelitis, is seen in quite a few cases. This is damage to the nervous system and manifests in different ways, so patients can show symptoms of meningitis, epilepsy, balance problems, muscle weakness and vision disturbance. It can mimic the symptoms of multiple sclerosis.

Causes of PHL

There are two reasons for ill health following a bacterial infection:-
Tissue damage

During the acute illness, bacteria cause damage to tissues in the patient’s body, by a combination of toxins and damage to the blood supply. This can lead to long-term changes in the function of internal organs but is not directly related to the bacteria, only to the damage they cause. Reduction in function of the liver and kidneys is one such outcome, but where the tissue damage is not too severe the body will heal over time.
Bacterial residency

In the body there are certain places, called immunologically privileged sites (IPSs) where the immune system is not very active, and bacteria can survive long after they have been killed in the rest of the body. These sites are usually places without a direct blood supply, such as the fluids within the eyeball and the structures of the brain and nervous system. In the rest of the body, the patient’s immune system reacts to leptospires and creates antibodies that will ensure they are killed within a few days, however in IPSs the supply of these antibodies, and the white blood cells that do the killing, are reduced. Bacteria can ‘hide’ in these sites but are kept trapped by the active immune system, so the symptoms tend to be concentrated on the same organs. We have very little direct evidence for the time bacteria can survive in this way, but it is certainly several months or years.

While they are present, leptospires in IPSs have two effects – they still leak toxins into the tissues, albeit at a quite low level, and this can cause slight inflammation or reduction in tissue viabililty. More importantly they can continually trigger the immune system at the border of the IPS, and the immune response to this constant prodding of white blood cells can be more severe than is required – in some cases it will cause an autoimmune response where the body’s immune system starts to attack ‘self’. It’s common for patients with PHL to show unexpected severe symptoms when exposed to leptospires a second time, as the autoimmune response is activated. It’s particularly true in the eyes and is the cause of recurrent symptoms in horses.


Treatment

There is no working treatment for PHL at this time which has shown itself to be effective on every patient – research conducted in recent years has shown promise in developing an immunological treatment program, however in the majority of cases supportive care is given. Maintaining a healthy diet with full nutritional balance is very important, and symptoms can be treated in isolation (with painkillers, etc.) but in many cases a repeat program of antibiotics has been able to increase the speed of recovery. The difficulty is that medication will only act on the persistent bacteria, and so any long-term tissue damage caused by the infection will need to heal at a natural rate – this can take several years and in severe infections there can be some permanent damage to tissues. Patients suffering poor helth after a leptospirosis infection should always discuss the issue of PHL with their physician, if necessary via a referral to a specialist in infectious and autoimmune disease. The symptoms are expected to reduce over time even without treatment, and so in many patients with only minor reduction in health it can simply be a waiting game.

sumber : http://www.leptospirosis.org/

APA ITU TRANSFER FACTOR 4LIFE.
Transfer factor adalah molekul pembawa maklumat halus yang memindahkan maklumat imuniti dari satu entiti ke satu entiti yang lain, seperti di antara ibu yang menyusukan bayi yang baru dilahirkan. Transfer factor terkandung di dalam kolostrum susu ibu (bagi mamalia) dan kuning telor (bagi burung dan reptilia). Klik DI SINI untuk maklumat asas yang lebih terperinci tentang transfer factor.Setiap manusia dan haiwan akan sentiasa diserang oleh berbagai-bagai jenis kuman, virus, kulat, hama, habuk, parasit dan perosak dari luar, yang boleh menyebabkan berbagai jenis penyakit. Sistem imunlah yang bertindak sebagai benteng bagi melindungi kita dari musuh-musuh ini. Apabila musuh datang menyerang, gambaran rupa musuh akan disimpan dalam ingatan molekul halus yang diberi nama transfer factor. Transfer factor bertindak sebagai ‘kamera penyimpan maklumat’ rupabentuk musuh tersebut. Maklumat tersebutlah yang dirujuk sebagai “kecerdikan” transfer factor. Apabila musuh datang menyerang lagi, sistem imun mudah mengenali mereka.Sehingga kini terdapat lebih dari 3,000 kajian klinikal dan rencana (dalam jurnal “peer-reviewed”) yang diterbitkan mengenai Transfer Factor. Beratus-ratus orang doktor dan saintis ternama dan dihormati di peringkat antarabangsa, yang berasal dari lebih 70 buah negara, telah mengesahkan keberkesanan dan keselamatan penggunaan Transfer Factor. Semenjak 50 tahun yang lalu, lebih dari 40 juta Dollar US telah dibelanjakan untuk penyelidikan dan data kajian menunjukkan bahawa Transfer Factor menawarkan faedah imun yang luar biasa.Semua penyakit dalam kategori jangkitan viral, penyakit berparasit, penyakit malignan, penyakit mikobakterial, penyakit bakterial, jangkitan fungus (kulat), penyakit autoimun dan penyakit neurologikal; dari yang ringan seperti selsema kepada yang berat seperti barah, sakit jantung, buah pinggang, kencing manis, bisa lutut, sawan, alergi dan sebagainya. Apabila seseorang itu berpenyakit, itu menunjukkan bahawa sistem imunnya sudah kalah. Transfer Factor akan mengejutkan sistem imun dari tidur dan merangsangnya untuk melawan mikro-organisma yang menyebabkan penyakit tersebut.

HUBUNGI SAYA UNTUK MAKLUMAT LEBIH LANJUT DI=

0163153132 (Zaidah)

August 4, 2010 Posted by | 4LIFE, artikel | , , , , , , , , , , , , | Leave a comment

APA ITU MELAMIN/MELAMINE DAN RISIKO PADA ANAK ANDA DAN KELUARGA ANDA.

Apakah itu Melamine ?

Melamine ialah bes organik yang terdiri daripada karbon,oksigen dan nitrogen. Bahan kimia ini kali pertama dihasilkan

oleh Justus von Liebig pada 1830 yang kemudiannya dihasilkan secara besar-besaran untuk kegunaan industri.

Seperti yang kita sedia maklum, melamine merupakan bahan yang digunakan untuk membuat pinggan mangkuk

melamine. Selain itu, melamine juga digunakan untuk menyelaputi permukaan plastik dan kayu.

Melamine mempunyai kandungan nitrogen yang tinggi.Oleh itu, dengan mencampurkan bahan kimia ini ke

dalam susu yang dicairkan akan mengaburi bacaan sebenar tahap protein pada susu tersebut. Penambahan

Melamine dalam makanan adalah menyalahi undang¬undang di bawah Akta Makanan 1983 dan

Peraturan¬Peraturan Makanan 1985.

Walaupun melamine sangat larut di dalam air dan mudah disingkarkan melalui urin, buah pinggang manusia tetap

mempunyai hadnya tersendiri. Akibatnya, pada dos melamine yang tinggi, ginjal tidak lagi mampu menyingkirkannya

dari tubuh badan manusia. Oleh itu, kepekatan melamine akan bertambah seterusnya membentuk kristal

yang turut dikenali sebagai batu karang.Pembentukkan batu karang ini akan bertambah saiz dari

semasa ke semasa yang akhirnya menyebabkan kegagalan ginjal yang serius.

Pada Mac 2007 yang lalu, satu kajian oleh pakar toksikologi,Perry Martos dari Universiti University of

Guelph mendapati ada satu lagi bahan kimia yang mendorong kepada pembentukan batu karang akibat

melamine iaitu cyanuric acid. Gabungan kedua-dua bahan kimia ini boleh menyebabkan pembentukan batu

karang yang sekaligus menyebabkan kegagalan ginjal.

Kesan melamine secara langsung mengakibatkan iritasi apabila terhidu dan bersentuhan dengan kulit atau mata.

Pengambilan melamine melalui makanan boleh mengakibatkan

:

kerosakan pada sistem pembiakan

•pembentukkan batu karang dalam ginjal dan

pundi kencing. Ini boleh mengakibatkan kegagalan ginjal terutamanya kepada bayi

Sebagai langkah proaktif ,semua pihak disarankan agar ibubapa dapat memantau gejala masalah buah pinggang seperti

bayi menangis tanpa sebab ketika kencing, kencing berdarah,dan tekanan darah tinggi pada bayi.

MAKLUMAT LANJUT SILA CLICK DI BAWAH.

melamine

http://en.wikipedia.org/wiki/Melamine

October 17, 2008 Posted by | artikel, buah pinggang, indonesia, KESIHATAN, malaysia | , , , , , , , , , , , , , | Leave a comment

MAKLUMAT LANJUT BERKENAAN TRANSFER FACTOR kebaikan untuk anda.

Transfer factor (TF) is an extract of low molecular weight containing several lymphokine molecules with immunomodulating properties. It has been described for the first time by Lawrence in the early ‘50s. It seems capable of transferring antigen-specific information to T-lymphocytes, and it is present in the lymphocytes of mammals and birds. It has been widely used over the past forty years in the treatment of viral, parasitic, fungal infections and allergic disorders, as well as immunodeficiencies, neoplasias, viz. cancer of the lung and prostate. Encouraging clinical results have also been observed in patients suffering from candidiasis and tuberculosis.

It has been thought that the potential of this compound for answering the challenge of unknown pathogenic agents is considerable as is its preventative potential. Data have shown that antigen-specific TF administered before a viral infection can prevent the onset of the disease, TF acting as a preventative vaccine based on cell mediated immunity.

Its molecular structure has only partially been unravelled. It seems that to a small peptide (ca. 5000 DA) are attached 2-3 ribonucleotides. However, this lack of knowledge did not prevent its clinical use since it is possible to produce large quantities of specific transfer factor in tissue culture or in immunised animals.


The first observations postulating the existence and establishing the concept of transfer factor dates from the early 1950s when H.S. Lawrence showed that delayed type hypersensitivity (DTH) to a given antigen could be transferred from one individual to another via cell-free extracts obtained from the leucocytes of an immunised donor. He assumed that this adoptive transfer of immunity was due to a molecule which he named transfer factor and he surmised that its molecular weight was less than 12,000 Daltons, as it filters through a standard dialysis bag. Since that time, all transfer factor preparations for clinical and experimental studies have been obtained by disrupting lymphocytes, dialysing the lysates and using the dialysed material for in vitro tests or in vivo clinical or animal studies.

Over fifteen hundred reports have confirmed Lawrence’s original observations and established that the dialyzable extracts thus obtained are capable of transferring specific immune information in vitro to naïve lymphocytes or in vivo to patients or experimental animals. This information concerns only cell-mediated but not humoral immunity, no de novo antibody production has ever been elicited by transfer factor, although it has been reported that it may modulate normal antibody production triggered by conventional immunisation.

Since the early 70’s, transfer factor has been used more often than not successfully for the treatment of viral, parasitic, fungal infections, and also as an adjuvant treatment in autoimmune, allergic and malignant disorders. Its apparent success is of no surprise since cell-mediated immunity (CMI) plays a crucial role in the control of infectious, parasitic, and autoimmune diseases, as well as cancer.

Because the TF extract is usually obtained from the total lymphocyte population containing helper and suppressor lymphocytes, it acts as a modulator of the immune system. It boosts the immune defences when required, e.g. in infectious, malignant or genetically impaired immune disorders or it exerts a suppressing effect on a hyperactive immune system when its down-regulation is desirable, e.g. in allergic disorders.

The mechanism of action of TF remains largely unknown, its activity, in addition to the transfer of immune information, is manifested as a non-specific modulation of the immune response. It is known that the dialyzable extract containing the TF molecules also contains other low molecular weight lymphokines e.g. IMREG 1 and 2. Thus, its non-antigen-specific immunomodulating activity, which may also play a role in the regulation of humoral immunity, is due to molecules present in the dialysate, but distinct from those responsible for the transfer of antigen-specific information.

It seems that the total dialysate obtained from peripheral lymphocytes is a cocktail of molecules that provide immunoregulatory activity, in addition to the adoptive transfer of novel antigenic specificities to the immunological memory of the recipient. Hence the qualification of TF as an immunomodulator, i.e. a lymphokine with immunomodulatory activity mediating adoptive immunity, in contrast with so-called active (antibody induction by immunisation with the corresponding antigen) or passive (mediated by antibody injection) immunity.

Nonetheless, and notwithstanding encouraging clinical results, many drawbacks have impeded research in this field and fast advances in understanding the nature and mode of action of this intriguing biological entity.

Until 1974, the only source of transfer factor was pooled leucocytes from blood donors, which limited material supplies, whereas the biological potency and specific activity of the extract varied from one preparation to another. Indeed, the precise antigenic specificity of the various batches of material used was practically unknown, but presumably large, since each batch reflected the collective immune experience of several individuals. For this reason, these preparations were improperly called “non-specific”, indicating multiple but unknown specificities.

Thus, despite several encouraging reports in the early 1970s, the clinical use of transfer factor was curtailed by the dearth of material with standardised and consistent activity. Similarly, biochemical studies were virtually impossible for lack of sufficient raw material for purification. In 1974, Viza and co-workers reported that TF with known specificities could be replicated in tissue culture, using a lymphoblastoid cell line. In the late 1970s, the same group and other investigators presented evidence that specific TF obtained from mammals after immunisation with a given antigen was also active in humans.

Nevertheless, in spite of the resolution of the supply problem, the controversy relating to this molecule was to grow. There are several reasons for this, and they pertain mainly to its unusual characteristics.

Nearly fifty years after Lawrence’s original observations, transfer factor remains an elusive and controversial entity, despite enormous laboratory efforts and several clinical studies with encouraging and sometimes spectacular results. Biochemical studies have already produced evidence that the molecule responsible for the transfer of the antigenic specificity is a small peptide with a molecular weight of approximately 5000 DA, and it has been suggested that two to three ribonucleotides are attached to the peptide. Unfortunately, attempts at sequencing the peptide have failed, because of the presence of a blocked amino terminus.

The transfer of antigen-specific CMI information by this extract is thought provoking, for it apparently contravenes essential tenets of immunology and molecular biology. However, since the experimental evidence supporting the antigen-specific transfer is uncontested, various hypotheses for understanding its mechanism have been proposed, but so far none has proven totally acceptable.

The specificity issue thus remains one of the essential problems. TF dialysates contain non-specific immunoregulatory molecules which can usually enhance and, in certain cases, down-regulate CMI. Two such molecules named IMREG I and IMREG II were identified by Gottlieb and his co-workers. Nevertheless, such moieties could play a role in enhancing a weak response to a ubiquitous antigen and thus provide false evidence of specific transfer. Studies undertaken with such rare antigens as coccidioidin or keyhole limpet haemocyanin (KLH) preclude non-specific enhancement of “lapsed” immunological memory. Several human and animal studies have established that TF is capable of transferring CMI to rare antigens that the recipient is unlikely to have encountered by chance.

The overall picture became more complex when two types of antigen-specific activity were described within the dialysates: a) inducer or helper activity, which is the activity of the conventional transfer factor and b) anti-transfer factor or suppressor activity. The distinctive properties of the two entities are as follows: transfer factor binds to its related antigen, suppressor factor binds to the related antibody (IgG); inducer factor is absorbed by T suppressor cells and macrophages, whereas suppressor factor is absorbed by T-helper cells and macrophages; inducer factor derives from T-helper cells, suppressor factor from T-suppressor cells.

Be that as it may, TF’s characteristics (low molecular weight, undefined chemical structure, unconventional mode of action, protein-like nature but resistant to most proteolytic enzymes) together with its biological properties (non-species specificity, transfer of antigen-specific information) have generated more opponents than supporters. And the frustration resulting from unsuccessful attempts to solve this multi-faceted riddle, especially the failure so far to unravel the molecular structure, apparently due to a blocked amino terminus of the peptide forbidding its sequence by conventional methods, has led scientists to doubt its very existence.

Despite promising results and hundreds of publications, failure to explain TF’s mechanism of action and define its molecular structure aroused doubts about its very existence. And even though recent work by Kirkpatrick has partially determined an amino-acid sequence (LLYAQDLEDN), thus giving some biochemical reality to the elusive moiety, no further publication has confirmed and complemented these data since.

Moreover, the pharmaceutical industry did not pay sufficient attention to this moiety because of the prohibitive costs of bringing a new medicine onto the market and the lack of patent protection (the impossibility of filing patents after decades of published academic work). In addition, the difficulties involved in production made commercialisation unviable. And a compound producing such astounding results as those described in the scientific literature, and which has not been on the market for so many years, gradually begins to lose its credibility. As for the commercial preparations obtained from colostrums and today sold via the internet, they definitely decrease the credibility of the product. Their acclaimed effects have never been tested or confirmed independently, neither in vitro nor in vivo, and the alleged clinical improvements cannot thus be differentiated from a placebo effect.


Even if some clinical reports of the ‘70s are subject to justified criticism, hundreds of studies have established the efficacy of transfer factor in treating several pathologies. Its lack of toxicity and the absence of side effects made the use of this extract appealing. Moreover, despite current scepticism, no publication has ever rejected reported clinical claims. An impressive number of clinical studies have demonstrated the efficacy of transfer factor in treating and even preventing viral infections. For instance, Steele and co-workers were able to protect leukaemic children receiving chemotherapy from varicella zoster virus infections using varicella-zoster-specific transfer factor. In the early 1980s, Viza and Dwyer described significant improvement obtained by the use of herpes-simplex-virus-specific transfer factor in treating patients suffering from recurrent genital and/or labial herpes. The clinical observations were later corroborated by experiments in a mouse model.

Other clinical studies have shown that specific transfer factor may produce a spectacular improvement in acute cytomegalovirus (CMV) infections. Moreover, in Africa, children suffering from Burkitt’s lymphoma (a tumour caused by EBV) treated over a long period with EBV-specific TF showed a significant decrease in the rate of relapses. Other viral infections e.g. hepatitis B respond equally well to specific TF.

Transfer factor treatment has proven to be helpful in several neoplasias. One should cite the pioneering work of Fudenberg and that of Pizza. Osteosarcoma, melanoma, breast, lung, prostate and kidney cancer patients have benefited from TF therapy.

Parasitic infections also respond to TF therapy as the data of Sharma, confirmed by Delgado, in treating cutaneous leishmaniasis suggest. Other parasitic diseases known to respond effectively to TF are schistosomiasis and cryptosporidiosis, and several reports cite positive results obtained in treating patients with mycobacterial infections such as lepromatus leprosy, mycobacterium fortuitum pneumonia refractory to antibiotic therapy and tuberculosis. Chronic mucocutaneous candidiasis, an immunodeficiency characterized by chronically relapsing Candida albicans infections also responds well to TF treatment.

HUBUNGI SAYA UNTUK MAKLUMAT LEBIH LANJUT DI= 0163153132(Zaidah)016-3143695 (AYIM)

___________________________________________________________________________________________________

A SHORT BIBLIOGRAPHY

Ablashi DV, Levine PH, De Vinci C, Whitman JE Jr, Pizza G, Viza D: Use of anti HHV-6 transfer factor for the treatment of two patients with Chronic Fatigue Syndrome (CFS). Two case reports. Biotherapy 1996; 9: 81-86.

Bilello P, Fishman M, Koch G: Evidence that immune RNA is messenger RNA. Cell Immunol 1976; 23: 309.

Boucheix C, Phillips J, Pizza G, Sartorio C, Viza D: Activity of animal transfer factor in man. Lancet 1977; i: 189-99.

Burger DR, Vandenbark AA, Dunnic W, Kraybill WG, Vetto RM: Properties of human transfer factor from KLH-immunized donors: Dissociation of dermal transfer and proliferation augmenting activities. J Reticuloendothel Soc 1976; 24: 385-402.

Chang Y, Cesarman E, Pessin MS et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266: 1865-1869.

Delgado O, Romano EL, Belfort E, Pifano F, Scorza JV, Rojas Z: Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis. Clin Immunol Immunopathol 1981; 19: 351-358.

Dwyer JM: The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: C.H. Kirkpatrick et al. (eds.) Immunobiology of Transfer Factor. Academic Press, New York 1983: 233-243.

Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menendez de San Pedro JC, Navea L, Ojeda M, Arana MJ: Inhibition of in vitro HIV infection by dialysable leucocyte extracts. Biotherapy 1996; 9: 33-40.

Fudenberg HH, Fudenberg HL: Transfer factor: Past, present and future. In E. Jucker (ed.): Annual Review of Pharmacology and Toxicology. Birkhäuser Verlag, Basel, Switzerland 1989: 475-516.

Fudenberg HH, Levin AS, Spitler LE, Wybran J, Byers V: The therapeutic uses of transfer factor. Hosp Pract 1974; 9: 95-104.

Fujisawa T, Yamaguchi Y: Postoperative immunostimulation after complete resection improves survival of patients with stage 1 nonsmall cell lung carcinoma. Cancer 1996; 78: 1892-1898.

Galbraith GMP, Fudenberg HH: Transfer factor. In: J. Stone (ed.) : Dermatologic Immunology and Allergy. Mosby, St. Louis, Mo 1985: 889-98.

Gottlieb AA, Sizemore RC, Gottlieb MS, Kern CH: Rationale and clinical results of using leucocyte-derived immunosupportive therapies in HIV disease. Biotherapy 1996; 9: 27-31.

Griscelli C, Revillard JP, Betuel H, Herzog C, Touraine JL: Transfer factor therapy in immunodeficiencies. Biomedicine 1973; 18: 220-227.

Hastings RC, Morales MJ, Shannon EJ, Jacobson RR: Preliminary results in the safety and efficacy of transfer factor in leprosy. In: M.S. Asher, A.A. Gottlieb, C.H. Kirkpatrick (eds.): Transfer Factor: Basic Properties and Clinical Applications. Academic Press, New York 1976: 465-76.

Kirkpatrick C.H, Transfer Factors: Identification of Conserved Sequences in Transfer Factor Molecules. Mol Med 2000; 6(4): 332-341. Kirkpatrick CH, Greenberg LE: Treatment of chronic mucocutaneaous candidiasis with transfer factor. In: A. Khan, C.H. Kirkpatrick, N.O. Hill (eds.): Immune Regulators in Transfer Factor. Academic Press, New York 1979: 547-62.

Lawrence HS, Borkowsky W: Transfer Factor – Current status and future prospects. Biotherapy 1996; 9: 1-5.

Lawrence HS: The transfer in humans of delayed skin sensitivity to streptococci M substance and to tuberculin with disrupted leukocytes. J Clin Inv 1955; 34: 219-32.

Lesser PG, Margarido L, Bolda W, Sartori SG, Hares WA, Freire CA, Fleury R, Montenegro MR, Leser W, Naspitz CK: Cell-mediated immunity in patients with Virchowian Hanseniasis before and after treatment with transfer factor. Hansenol Int J 1980; 5(1); 3-27-34.

Levin AS, Byers VS, Fudenberg HH et al.: Osteogenic sarcoma: Immunologic parameters before and during immunotherapy with tumor specific transfer factor. J Clin Invest 1975; 55: 487-499.

Levin AS, Spitler LE, Stites DP, Fudenberg HH: Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory response to therapy with transfer factor. PNAS 1970; 67: 821.

Masi M, De Vinci C, Baricordi OR: Transfer factor in chronic mucocutaneaous candidiasis. Biotherapy 1996; 9: 97-103.

McMeeking A, Borkowski W, Klesius PH, Bonk S, Holzman RS, Lawrence HS: A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infec Dis 1990; 161: 108-12. Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza D: Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 1996; 9: 61-66.

Metcalf JF, John JF Jr, Wilson GB, Fudenberg HH, Harley RA: Mycobacterium-fortuitum pulmonary infection associated with an antigen-selective defect in cellular immunity. Am J Med 1981; 71: 485-491.

Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ, Nkrumah F: Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anticanc R 1990; 10: 1183-1187.

Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C, Levine P: Regression of progressive lymphadenopathy in a young child with acute CMV infection following the administration of transfer factor with specific anti-CMV activity. Lymphok Res 1985; 4: 237-241.

Pilotti V, Mastrorilli M, Pizza G, DeVinci C, Busutti L, Palareti A, Gozetti G, Cavallari A: Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996; 9: 117-121.

Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH, De Vinci C, Viza D: Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy 1996; 9: 41-47.

Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D: A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy 1996; 9: 123-132.

Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R: Orally administered HSV-specific transfer factor (transfer factor) prevents genital or labial herpes relapses. Biotherapy 1996; 9: 67-72.

Pizza G, Viza D, Roda A, Aldini R, Roda E, Barbara L: Transfer factor for the treatment of chronic active hepatitis. N Eng J Med 1979; 300: 1332.

Prasad U, bin Jalaludin MA, Rajadurai P, Pizza G, De Vinci C, Viza D, Levine PH: Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy 1996; 9: 109-115.

Rappaport FT, Lawrence HS, Millar JW, Pappagianis D, Smith CE: Transfer of delayed hypersensitivity to coccidioidin in man. J Immunol 1960; 84: 358-67.

Sharma MK, Anaraki F, Ala F: Preliminary results of transfer factor therapy of persistent cutaneous leishmania infection. Clin Immunol Immunopathol 1979; 12: 183-190.

Spitler LE, Levin AS, Stites DP, Fudenberg HH, Pirofsky B, August CS, Stiehm ER, Hitzig WH, Gatti RA: The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest 1972; 51: 3216-24.

Steele WR, Myers MG, Vincent MM: Transfer factor for the prevention of varicella zoster infection in childhood leukaemia. N Eng J Med 1980; 303: 355-59.

Steele WR: Transfer factor and cellular reactivity to varicella zoster antigen in childhood leukaemia. Cell Immun 1980; 50: 202-89.

Vich JM, Viza D: Specific suppressor dialysates from mice. In: C.H. Kirkpatrick, D.R. Burger, H.S. Lawrence (eds.): Immunobiology of Transfer Factor. Academic Press, New York 1983: 197-202.

Vich JM, Garcia JV, Engel P, Garcia PA: Transfer to man of sensitization to Keyhole Limpet Haemocyanin by mouse transfer factor. Lancet 1978; i: 265.

Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A, Müllet-Bérat N: In vitro production of transfer factor by lymphoblastoid cell lines. Transplant 1975; VII (suppl. 1): 329-333.

Viza D, Lefesvre A, Patrasco M, Phillips J et al.: A preliminary report on three AIDS patients treated with anti-HIV specific transfer factor. J Exp Path 1987; 3: 653-659.

Viza D, Vich JM, Minarro A, Ablashi DV, Salahuddin SZ: Soluble extracts from a lymphoblastoid cell line modulate SAIDS evolution. J Virol Met 1988; 21: 241-253.

Viza D, Vich JM, Phillips J, Rosenfeld F, Davies DAL: Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555-562.

Viza D, Vich JM, Phillips J, Rosenfeld F: Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27-30.

Wilson GB, Metcalf JF Jr, Fudenberg HH: Treatment of mycobacterium-fortuitum pulmonary infection with “transfer factor” (TF): New methodology for evaluating TF potency and predicting clinical response. Clin Immunol Immunopathol 1982; 23: 478-483.


BERMINAT UNTUK MENCUBA TRANSFER FACTOR?

HUBUNGI SAYA UNTUK MAKLUMAT LEBIH LANJUT DI= 0163153132(Zaidah)016-3143695 (AYIM)

October 8, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, malaysia | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

4LIFE TRANSFER FACTOR DI AMR(ULASAN PERUBATAN DI AMERIKA)

SEKIRANYA BERMINAT UNTUK MENCUBA,SILA HUBUNGI KAMI SEMULA.

October 7, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, malaysia | , , , , , , , , , , , | Leave a comment

Transfer Factor knowledge.(ILMU TRANSFER FACTOR 4LIFE)

MORE KNOWLEDGE IN TRANSFER FACTOR,CLICK BELOW

dr-bennett-breakthrough-in-immunity

transfer-factor-plus

September 21, 2008 Posted by | 4LIFE, artikel, KESIHATAN, malaysia | , , , , , , , | Leave a comment

Kolestrol rendah meningkatkan peluang kanser??

Low Cholesterol Levels Increases Cancer Risk- American College of Cardiology

For years, I’ve been telling my patients that the medical establishment’s obsession with lowering cholesterol to prevent heart disease is causing more harm than good.

If your doctor continues to get you worried about your high cholesterol levels, here’s a bit of news for you…

In fact, your high cholesterol may be protecting you from cancer.

Today, I’ll explain the truth behind the myth of cholesterol, and show you how to achieve heart health naturally.

A new study published in the Journal of the American College of Cardiology revealed that driving down cholesterol levels actually increases the risk of cancer.

Researchers at the Tufts University School of Medicine found that among people taking “statin” drugs – like Lipitor and Zocor – there was a higher rate of cancer. Although the link between the drugs and cancer wasn’t clear, there was no doubt that drastically low cholesterol levels correlated to cancer risk.

The big drug makers continue to sell the notion that the best way to fight heart disease is to lower LDL levels, the so-called “bad” cholesterol.

Yet 75 percent of people who suffer heart attacks have normal cholesterol levels.

It makes sense that low cholesterol levels are linked to cancer because cholesterol is one of your body’s basic building blocks. You need it to produce testosterone, to build and repair cell membranes, and to preserve your nerve cells through the formation of the protective “sheaths” that cover them.

Starving your body of this critical substance will lead to other health problems. We already know that extremely low cholesterol levels result in muscle weakness, fatigue, depression, decreased sex drive, and “brain fog.” This new research shows that there may be even more deadly consequences.

What really matters is not low “bad” cholesterol, but high levels of HDL, the so-called “good” cholesterol. As long as you have a high HDL count – 75 to 80, for example – it doesn’t matter whether your total cholesterol is 150 or 350. A high HDL will always keep your risk of heart disease extremely low.

So why haven’t you heard this already? It may be because there’s no drug that effectively raises good cholesterol levels. You can only effectively do it naturally.

Consume natural fats. Avoid processed or fast foods containing “trans” fats – these man-made substances were never meant for consumption, and your body doesn’t know what to do with them. They wind up clogging your arteries and putting you on the fast track to heart disease.

Instead, get your fat from free-range or grass-fed animals, eggs, nuts, and unprocessed vegetable oils. These are some of the healthiest foods you can eat. (As with all foods, look for organic or minimally processed options whenever possible.)

The health benefit of these natural fats comes from their balance of Omega-3 and Omega-6 fatty acids. Your body needs both but, as with cholesterol, they have to be in balance. Omega-3s are great for your heart. They’ve been shown to prevent irregular heartbeat, reduce clogging of the arteries, lower blood pressure, and decrease inflammation in body tissues.
If you stick to eating natural fats, you’ll automatically get the right ratio of Omega-6 and Omega-3, which is about 2:1. As an added bonus, you’ll automatically raise your “good” cholesterol levels and you’ll reduce your risk of cancer.

To Your Good Health,

Al Sears, MD

August 25, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, KEWANGAN, malaysia | , , , , , , , , , , , , , , , , , , , | Leave a comment

ILMU KESIHATAN 4LIFE DAN PRODUK 4LIFE

August 20, 2008 Posted by | 4LIFE, artikel, BARAH, kanser, KESIHATAN, KEWANGAN, malaysia | , , , , , , , , , | Leave a comment

PENEMUAN TERBARU DALAM KESIHATAN JANTUNG (baca sekiranya ada sakit jantung atau keluarga anda mengidapinya)

ATHEROSCLEROSIS
A BREAKTHROUGH in HEART HEALTH
TF Cardio: “Targeted Transfer Factors”

Recently, the prestigious journal, Scientific American*, reported the results of a study on a breakthrough in the understanding of heart disease. For the past few years, a number of scientists have been re-evaluating the root cause of heart disease. Health professionals throughout the world have been concerned and confused by the increase in the incidence oheart disease. The article in Scientific American authored by Dr. Paul Libby from Harvard University explained the new understanding of heart disease.

During the past few decades, the general public has experienced a continuous increase in heart disease in spite of an increase in exercise, nutritional consumption and a decrease in fat consumption. The haunting question has been why? Last year, more than one million people died of heart disease. It is estimated that more than 60 million people in the United States have some form of cardiovascular problem. The fact that 40% of individuals that experience heart attacks do not have high cholesterol levels and exhibit no symptoms of circulatory problems is an unexplained phenomenon in cardiovascular health. Underscoring the seriousness of this problem was the discovery of how early in life heart disease begins. In a recent study of autopsies of individuals that died in automobile accidents, it was found that the majority of 16-34 year-olds suffered from the beginning stages of heart disease.

Recently, studies have revealed the true cause of heart disease. This discovery explains the increase in heart disease over the past few decades in spite of all the efforts to reduce heart disease. Research has found that the universally accepted hypothesis for the cause of heart disease has been wrong. Cardiologists throughout the world have been wrong on the cause of heart disease and wrong on how to address heart disease. It was once believed that over a period of time cholesterol clogged the artery like a drain becomes clogged. This study found that heart disease actually begins with an immune system dysfunction.

Scientists found that there are two basic pathways through which the immune system becomes involved in a cascade of events that lead to heart disease. One of these pathways begins with an infection in the lining of the artery. There are six known pathogens that are found within the lining of the artery that may be involved in triggering an initial immune system response. The second pathway involves modified cholesterol entering the lining of the artery. In response to these pathways, the immune system creates a cascade of inflammatory responses that initiate the process that leads to heart disease.

The Harvard University researcher discovered the greatest danger was not cholesterol building up inside the artery channel but cholesterol building up inside the lining of the artery. The cholesterol actually explodes into the channel of the artery from the lining, often without notice and in seemingly healthy individuals with a dysfunctional immune system being the primary agent of disease. Scientists found that even individuals with strong immune systems in other areas can suffer from this condition.

In 1997, David Lisonbee had a theory that heart disease was related to a dysfunctional immune system. In 1998, he commissioned Dr. Hennen to initiate a research project that would address the connection between the immune system and heart disease. In order for Dr. Hennen to achieve this goal, he had to take the science of transfer factors to a level that had never been achieved before by any other scientists. In August of 2002, all of his extensive research paid off in the unveiling of TF Cardio.

In order to apply this breakthrough to cardiovascular health, these researchers had to develop new biotechnology. Transfer factors were bio-engineered to target pathogens hiding in the lining of arteries. These pathogens are believed to create the cascade of events leading to inflammation and heart disease. Also, the transfer factors have the ability to balance the immune system in the lining of the arteries. It appears that a balanced and functional immune system is a key to the health of the cardiovascular system.

Transfer factors contain inducers and suppressors that work together to balance or modulate the immune system. It is believed that the suppressors in transfer factors will reduce inflammation. Inflammation is a cause of some cancers, certain types of heart disease and other health conditions. Although targeted transfer factors form the core ingredients that make this formulation effective and exceptional, several other important nutrients have been included in order to address other issues in the health of the cardiovascular system. Nutrients such as red rice brand extract, CoQ10, and arginine have been included in order to provide the best overall natural approach to a healthy cardiovascular system.

Research has indicated that red rice brand extract can be beneficial in maintaining healthy levels of cholesterol. CoQ10 is an enzyme that is involved in the production of cellular energy in every cell in your body. CoQ10 interacts with other natural chemicals in the mitochondria. Every cell in your body must have energy to stay alive and properly perform its function. The heart is a muscle that is constantly working and under pressure. A great deal of energy is expended through the heart muscle. More than 4,000 studies have been conducted on CoQ10 in conjunction with a healthy heart.

Arginine is involved in the production and regulation of nitric oxide. Each time the heart beats, the miles of circulatory system contract and relax. The process is very important to the delivery of blood to every cell in the body. Nitric oxide is chemically involved in this process.

Magnesium and potassium are included in this formula. These minerals are involved in the body’s attempt to maintain healthy blood pressure. Copper and Zinc are included because of their influence on the immune system and in maintaining healthy levels of “good” cholesterol or HDL. Selenium, folic acid, vitamins B-12, C, E, and the amino acid lysine are included to decrease lipid oxidation, decrease platelet aggregation, reduce homocysteine levels and affect a number of other important body functions.

Heart disease is the number one killer. Many people live compromised lives because of an unhealthy cardiovascular system. A great number of individuals that experience sudden heart attacks do not have high cholesterol levels or any signs of heart problems. Our knowledge of nutrition and good health has greatly increased in the past few years. Many individuals are taking a proactive approach to health.

4Life Research has established itself as the leader in cardiovascular health by being the first scientists in the world to discover and patent this new technology. Presently, this is only technology that utilizes a nutritional pathway in addressing the most recent discovery reported by researchers from Harvard University.

SILA HUBUNGI SAYA UNTUK KETERANGAN LANJUT.

Puan Zaidah

WINNER4LIFE MELAKA

+600163153132

email: helplinemy@yahoo.com

July 20, 2008 Posted by | 4LIFE, artikel, darah tinggi, indonesia, JANTUNG, KESIHATAN, malaysia | , , , , , , , , , | Leave a comment

TESTIMONI PENGUNA TRANFER FACTOR DI MALAYSIA DAN SINGAPORE

PENAWAR AJAIB 4 LIFE

PENAWAR AJAIB 4 LIFE

Hari ini baru lah saya berani untuk berkongsi testimonial saya pada anda semua kerana saya benar2 yakin semput saya 99% sembuh Alhamdulillah

Nama saya Jamilah Abdollah berusia 38 tahun. Saya ingin berkongsi dengan anda semua kerana ini mungkin boleh dijadikan contoh pada kawan2 anda yang masih belum yakin dengan Tranfer Factor dimana ia dapat membantu dari segi kesihatan dan juga FINANCIAL PROBLEM.

Selama 27 tahun saya menderita penyakit semput bole dikata cronic kerana dalam masa 1 bulan hampir 2 atau 3 kali saya harus berjumpa dengan Dr Chan (Family Dr since my age of 11yrs old). Dari umur saya 11 tahun sehingga lah umur saya 38 tahun masih berjumpa dengan Dr Chan untuk mengambil ubat semput ia itu 2 type of tablet ( Dhasolone & Zenmolin ) dan 2 type of spray ( Ventolin Evohaler & Clenil ). Spray harus digunakan 4x sehari dan ubat 2 tablets each hampir setiap hari. Kadang-kala saya harus ke hospital untuk mendapatkan oxigen dan injection and sometime kena warded. Ubat2 ini ada side effect nya 1st tangan saya tak kuat dan ia sentiasa menggigil dan dejupan jantung laju. Apabila diserang semput saya selalu stress , marah2 & sakit kepala sehinggakan urat2 dikepala timbul.

Dalam masa 10 tahun saya mencuba bermacam-macam produk dari yang mahal sehinggalah yang murah tetapi belum ada satupun yang dapat membantu semput saya sehingga lah 5 bulan yang lepas suami saya Shafie telah berjumpa dengan Rosli (my upline) dimana beliau telah mengenalkan tentang Tranfer Factor. Dengan saranan Rosli saya telah mengambil 18 biji for 3 days ( 6 biji sehari ) dan sehingga hari ini semput saya belum attack Alhamdulillah. Saya sudah dapat naik tangga sehingga 4 tingkat , cycling , makan pulut dengan air coke (favorite food & drink) kalau dulu pantang kena sikit aje semput dan berat badan saya bertambah seimbang dengan height saya dan makan lebih selera. Saya bersykur pada Allah kerana akhirnya telah dimakbulkan doa saya.

Now daily taking 1 advance or plus & 1 cardio

Disini sebagai iktibar jangan sekali-kali kita putus asa kerana setiap doa dan usaha yang kita lakukan , lambat atau cepat pasti akan dikurniakan dan yang penting YAKIN akan apa yang kita minta dan buat.

Saya Ab Karim dari Johor. Saya juga mengalami asthma bronchitis lebih kurang 5 tahun dulu, mungkin kerana umur saya dah melebihi 52 tahun. Saya mencuba dua benda, iaitu TF advance 2 biji sehari dan juga preventive spray of Symbicort Turbohaler (sekali spray pagi dan sekali petang), sejak 6 bulan dulu. Setakat ini saya tidak pernah diserang asthma lagi. Saya telah mencadangkan kepada beberapa kawan yang mengalami kesulitan yang sama, dan telah nampak kesan positif nya.Saya telah mendaftar sebagai pengedar 4life TF sejak 5 bulan dulu, tetapi belum diamond lagi.Namun begitu saya akan teruskan, sebagai pengedar, atau lebih sebagai pembekal kepada kawan2 yang tak nak jadi pengedar lagi. Saya menjual pada harga pengedar sahaja kerana nak tolong kawan2 agar sihat. Walaupun begitu secara keseluruhan saya dapatlah RM500 – 600 sebulan dari usaha minimum saya tu. Pengalaman yang saya dapat dari kawan2 yang telah lebih sihat ini saya gunakan untuk mencuba mengedar kepada pelanggan baru. Nampaknya kesan positif yang paling ketara bila menggunakan 4life TF ialah bagi orang2 tua (50-60 tahun, wanita yang sering sakit belakang dan lutut). Terdapat beberapa pak cik dan mak cik yang tak lupa telepon saya setiap kali duit pencen keluar, untuk membuat order bagi bulan berikutnya. Untuk mempastikan saya ada stok setiap kali mereka call, saya order 12 TF for the price of 10, every time, jadi dah ada untung 2 botol. Dan commision nanti adalah dalam RM400.Biasa nya pelanggan tetap saya ni akan beli 16 – 24 botol sebulan, jadi walaupun saya jual pada harga pengedar, saya masih dapat pocket money yang agak lumayan. Downline saya tak banyak, dan kurang active, kerana saya sendiri tak begitu active. Anyway kalau ada sesiapa yang mempunyai pengalaman seperti ini harap dapat kita kongsi bersama.

Anak saya berumur 11 tahun, hari pertama terkena demam campak, bintikbintik keluar di seluruh badan.
Dia merengek dan tidak mahu makan. Saya beri dia 3 biji TF pada hari itu. Hari kedua, dia ada selera makan,
tak merengek lagi, bintik makin banyak… Hari ketiga bintik-bintik kurang, dia ceria macam biasa. Hari ke-empat,
kulit dia licin macam sediakala. Semua jiran saya pelik!
Anak-anak mereka baik selepas satu minggu kena demam campak. Terimakasih Winners4Life dan TF!
– Abdul Jalil, Kulai,JOHOR

TF Hebat!! Pesakit wanita yang menghidap “mild cerebral palsy” mengadu
batuk dan selsema lebih dari 3 bulan, tidak berhasil dengan berbagai
ubatan, tetapi sembuh dalam masa 2 hari dengan hanya 2 biji TF dua kali
sehari. – Doktor Sani, Klinik Adham, Kota Tinggi –
Saya hidap semput sejak 4 tahun lalu. Alhamdulillah, selepas 2 bulan
mengambil TF anjuran Winners4Life, saya bertambah sihat, dapat tidur
malam, dan kurang terkena serangan. – Pn Ah’Esah Ahmad – Jelapang
Road, Singapura

Anak saya, kalau datang bulan, akan kena senggugut teruk sehingga
menangis kesakitan! Sejak makan TF, senggugut tak pernah datang lagi.
Thank you Winners! – Halida, TNB Batu Pahat –
Saya mengidap sakit lumpuh sejak 2 bulan lalu. Dan sebelah anggota
badan tak dapat bergerak. Setelah mengambil TFAdv selama 4 hari sahaja,
5 biji siang, 5 biji malam, saya sudah boleh bergerak dan beransur pulih.
Alhamdulillah. Terima kasih En Nawi dan Winners4Life. Hussein
Deraman – Kuantan Pahang.

Ibu saya mengalami kencing manis selama 15 tahun, dan berada dalam
keadaan yang teruk. Jari-jari tangannya hampir reput dan menanah. Setelah
mengambil TF selama 5 hari, keadaannya telah pulih dengan begitu ketara,
dan kadar gula kembali normal. Dalam 2 minggu, infeksi dan penanahan
menjadi kering. Terima kasih En Akram dan En Zul dari Winners4Life
kerana mengenalkan produk ini kepada saya. Daripada Ahmad Rodzi, Alor
Star.

Pesakit wanita mengidap penyakit jangkitan kulat (keputihan vagina)
selama 6 bulan dan telah dirawat oleh 3 doktor pakar sakit puan, tetapi tidak
berhasil. Selepas mengambil 2 dose TF, 2 biji sehari, keputihannya terus
“clear!” – Daripada Dr Sani, Klinik Adham Kota Tinggi –
Saya amat terkejut dan bersyukur kerana masaalah penyakit “degupan
jantung” saya kembali normal walau baru saja mengambil 4 biji TF
Advanced selama 2 hari. Terima kasih Winners4Life! – Wan Fuziah, JB

Lelaki umur 40 tahun, kena penyakit TB infeksi tenosynovitis hingga kaki
kanannya hampir lumpuh. Setelah saya berikan TF sebanyak 4 biji sehari,
keadaannya pulih selepas 2 hari. Daripada Dr Sani, Klinik Adham Kota
Tinggi –

Lebih 10 tahun saya tidak dapat hamil dan juga sakit thyroid. Tempoh
hari saya diserang demam selsema dan ibu beri saya 10 biji TF. Dalam 2
hari, sakit saya reda, dan selepas 2 bulan, doktor sahkan saya sudah hamil.
Saya cukup gembira. Alhamdulillah. Terima kasih Winners4Life.
Daripada Puan Fazilah, Tampines Singapore,
Sertailah Winner4Life, untuk sama-sama menyebarkan “Transfer Factor” yang juga dikenali sebagai “Molekul Ajaib”. Insyaallah mujarab, maju & berkat.
Selama lebih 10 tahun saya mengidapi migraine yang kronik! Awal
Februari lalu, saya mencuba TF 2 biji pagi dan 2 bji malam. Selepas 3 hari
sahaja, migraine saya terus hilang! Alhamdulillah, dan thank you
Winners4Life! Pn Jamilah, Kulai, Johor –

Sejak mengambil TF, saya telah dapat semula deria bau saya yang hilang
sejak 4 tahun lalu akibat kemalangan jalanraya yang teruk. Saya telah
berbelanja hampir RM50,000 untuk rawatan. TF telah bantu saya bebas
dari bengkak dan infeksi di mata kiri saya sejak kemalangan dulu. TF
banyak membantu saya dapat kembali kekurangan yang saya alami sejak 4
tahun dulu. Terima kasih Transfer Factor dan Winners4Life. Cikgu
Zainordin, Benut, Johor -

Leader Nutrimetic menalifon dan memberitahu saya dia rasa puashati
dengan TF. Dengan hanya 2 biji sahaja, masaalah sakit urat yang dia
hidapi sejak 5 tahun, telah settle. Dia akan join bila balik dari KL nanti.
Chegu Zul, Alor Star –

Kawan saya mengalami sakit lutut hampir 2 tahun. Pelbagai ubat yang
telah doktor berikan, namun tidak dapat menyembuhkan sakit lututnya.
Setelah mengambil TF 2 biji pagi dan 2 biji malam, keadaan lutut kawan
saya telah baik seperti sediakala. Terima kasih En Zul dan Akram Din dari
Winners4Life! Daripada Ahmad Rodzi, Alor Star
Saya sedang mengandung & selalu merasa tidak sihat & mabuk. Saya juga
sudah keguguran sebanyak 5 kali sebelum ini. Sejak memakan TF, saya
rasa sihat, merasakan tenaga seperti sediakala & tidak mengalami mabuk
lagi. Saya kini telah melahirkan dengan selamat. Terima kasih kepada TF
& Winners4Life! Pn Hani, Tampines, Singapore -

Saya sudah mengidap penyakit migraine dan juga buasir selama beberapa
tahun. Kekadang hari saya terpaksa memakai tuala pelekat wanita untuk
mengawal kesan buasir saya. Saya suka bersukan dan ini sangat
memalukan dan sangat menyusahkan saya. Saya amat terkejut apabila saya
mula mengambil TF untuk migraine saya, saya dapati masaalah buasir saya
juga dapat diatasi sekali gus! Terima kasih Winners4Life dan Puan Sheri
Din. Daripada En Ahmad Hussein – Trengganu –

Saya mengalami stroke (angin ahmar) sejak satu setengah tahun lalu.
Sebelah kaki & tangan saya tidak dapat berfungsi & lidah juga menjadi
kelu. Setelah mengambil TF dari Winners4Life selama sebulan setengah,
sebanyak 4 botol, kini saya sudah boleh berjalan & saya juga dapat
bercakap dengan lancar. Alhamdulillah. Terima kasih pada Anna &
Winners4Life kerana menganjurkan penawar hebat ini! Daripada Che
Gayah, Kulai, Johor.

Saya menderita sakit lutut yang sangat berat. Saya tidak dapat duduk
bersila lebih dari 1 tahun & tidak boleh menaiki tangga & juga terpaksa
bersolat duduk. Lutut saya keras dan tidak dapat berbengkok menyebabkan
saya terpaksa merangkak apabila bangun dari duduk berlunjur dilantai.
Selepas 2 bulan memakan TF sebanyak 6 biji sehari, saya kini boleh duduk
bersila, menaiki tangga & solat berdiri. Alhamdulillah! Terima kasih
Winners4Life. Daripada Pn Rugayah, Kulai, Johor.
Saya mempunyai anak yang terencat akal, yang selalu terkena sawan, sejak
dari umur 1 tahun hingga kini 17 tahun. Apabila sawan menyerang, dia
akan jatuh dan cedera. Banyak kali telah luka di muka dan kepala dan
beberapi kali patah di tangan. Alhamdulillah, sejak mula memakan TF 2 biji
sehari, dia tidak diserang sawan lagi. Pn Mahimah, Kuantan –

Ibu mertua saya hidap diabetes (kencing manis) yang kronik sejak 4 tahun
lalu. Ibu jari kakinya luka lebih satu bulan dan tekanan darahnya naik
tinggi. Setelah memakan Transfer Factor 1 minggu, lukanya kering
sepenuhnya dan tekanan darahnya turun. Terima kasih kepada insan yang
mengenalkan Transfer Factor molekul ajaib ini, kepada saya. Daripada En
Azmi Elias, Masai Johor

Saya menghidap kencing manis hampir 10 tahun. Minggu lalu, saya
mula mengambil TF, 2 biji pagi dan 2 biji petang. Badan saya rasa sangat
ringan, tidur lena dan tak perlu bangun malam buang air kecil! Thank you
En Akram dan Winners Group! Daripada Alawdeen Trading & Provision
Shop, Margaret Drive, Singapore.

Suami saya menderita kanser perut, dan perut dia telah “dibuang” melalui
surgery, tetapi dia mengalami pendarahan dan keracunan darah yang teruk.
Dia di ICU buat beberapa waktu dan sudah mula menulis wasiat untuk
keluarga. Harapan untuk terus hidup terlalu tipis, mengikut pandangan
doktor. Dia kemudian dihantar pulang dari hospital tanpa sebiji ubat pun.
Saya amat terharu melihat keadaannya. Dia tidak dapat berjalan, dan
menjadi kurus sehingga tinggal kulit dan tulang sahaja. Saya
mengusahakan berbagai ubatan tradisional tetapi tiada yang memberi kesan
yang dikehendaki. Namun, setelah kami diperkenalkan dengan produk
Transfer Factor dari Winners4Life, keadaan suami saya terus berubah.
Saya memberi dia 9 biji sehari pada permulaan selama 2 minggu dan
kemudian diturunkan 4-6 biji sehari. Alhamdulillah, dia sudah sihat
sekarang. Dia boleh berfungsi seperti biasa. Badannya sudah naik. Selera
makan sudah pulih seperti biasa. Rambutnya tumbuh kembali. Dan tenaga
batinnya kembali normal. Saya amat bersyukur. Saya rasa seperti dia mati
hidup kembali! Terima kasih pada Chegu Azman dan Pn Sheri Din.
Daripada Norbaba, Sandakan, Sabah –

Saya menderita sakit buah pinggang & menjalani dialisis 3 kali seminggu
. Sebelum makan TF anjuran Winners4Life, saya selalu penat, terlalu lesu
& berbaring sahaja. Sekarang tenaga saya sudah pulih & dapat bekerja
kembali untuk mencari nafkah keluarga. Sel darah merah saya juga sudah
bertambah, menurut doktor. Alhamdulillah. Daripada En Khalid, Kulai,
Johor.

Anak saya sudah menghidapi sinus sejak dia berumur setahun, dan
sekarang dia sudah berumur 17 tahun. Setiap pagi bila dia menghembus
hingus, nescaya sinki bilik mandi akan tersumbat kerana terlalu banyak
hingus yang pekat dan hijau. Dia telah menjalani 2 operasi tetapi penyakit
sinus dia tidak juga sembuh. Alhamdulillah, setelah mengambil Transfer
Factor selama 2 minggu, penyakit dia telah sembuh sepenuhnya! Jutaan
terimakasih kepada Chegu Jalil dan Winners. Drpd Pn Zuraidah, Skudai
Johor,

Pada bulan February, volume 3 level saya, hanya 700LP. Pada bulan
March, volume 3 level saya meningkat kepada lebih 6,000LP! Dan saya
berjaya mencapai pangkat Diamond, dengan hanya mengedarkan flyer
“Raja Penawar” dari kumpulan Winners sahaja! Gunakanlah flyer hebat
ini! Insyaallah anda juga akan berjaya! Ida, Singapura/JB

Walaupun belum ramai ahli dibawah kumpulan saya, bonus bulan
pertama saya dalam 4Life Research adalah RM1,418! Ini adalah kerana
produk TF yang cukup berkesan, persen bonus yang tinggi dan sokongan
kumpulan Winners4Life! Terima kasih pada upline saya, Ina dan Man Batu
Pahat dan En Sadik Din. Daripada Johan, Pasir Gudang,

Walaupun saya baru menyertai 4Life dan bergerak selama 2 minggu sahaja,
saya telah terima bonus pertama yang mengejutkan – RM2,368!
Sebelum ini saya biasa sertai banyak MLM tapi tak pernah terima bonus
setinggi ini dalam waktu yang cukup singkat. Dijangkakan bonus saya akan
meningkat lebih RM5,000 pada bulan depan. Terima kasih Winners4Life
kerana memberi saya peluang yang tiada tandingannya ini. Man, Batu
Pahat –

Sebelum menceburi bidang MLM, saya adalah seorang engineer, dan telah
bekerja di luar negeri buat beberapa tahun. Semasa krisis ekonomi melanda
rantau Asia, saya telah kehilangan pekerjaan. Perkara ini membuat saya
menyedari bahwa masa depan saya sebenarnya diluar kawalan saya sendiri.
Walaupun sekiranya saya berjaya mendapatkan pekerjaan yang lain, ini
tidak menjamin yang saya tidak akan dibuang kerja lagi. Maka saya
mencari satu peluang yang mana saya sendiri menentukan masa depan saya,
dan saya tidak bergantung kepada pemerintah, korporat atau boss. Saya
memilih untuk menjadi boss kepada diri saya sendiri. Diwaktu itu, saya
terus menceburi bidang MLM sepenuh masa selama tiga tahun, tetapi
malangnya tidak membuahkah hasil yang saya harapkan. Ini adalah kerana
saya tidak berpengalaman memilih syarikat yang boleh membawa saya ke
mercu kejayaan. Didalam bisnes ini, “timing” memainkan peranan yang
sangat besar. Syarikat yang saya ceburi dulu memasarkan produk kesihatan
biasa seperti vitamin, herba dan mengkudu yang trend nya sudah berlalu.
Tetapi di 4Life, saya memasarkan produk inovatif, unik & hebat yang tiada
persaingan langsung di pasaran global! Dan plan pemasaran 4Life memberi
ganjaran yang hebat kepada ahli sambilan dan ini memberi kestabilan
kepada kumpulan saya. Alhamdulillah, bersama 4Life dan Winners
Group, kini saya telah mula merasai kehebatan MLM yang selama ini saya
impikan. Akram Din, Singapura/Malaysia -

Saya sudah beberapa tahun menerajui kumpulan MLM syarikat
antarabangsa secara fulltime, tetapi tidak pernah terjumpa produk sehebat
Transfer Factor! Disebabkan oleh keajaiban produk ini dalam membantu
ramai orang (dari kanak-kanak kecil sehingga orang-orang tua) mengatasi
bermacam-macam penyakit (termasuk sinus, allergi, gatal-gatal, kencing
manis, darah tinggi, kanser, gout, bisa sendi, gastrik, sakit gigi, migraine,
buasir, demam, selsema, psoriasis, sawan, lemah IQ dan bermacam-macam
lagi!), kumpulan saya iaitu Winners Group telah menjadi kumpulan yang
begitu hebat, cemerlang dan disegani! Alhamdulillah! Plan pemasaran
4Life pula tiada tandingannya di pasaran. Sistem bonus “Unilevel
Compressed” memberi pulangan yang sangat besar untuk semua ahli
termasuk ahli-ahli baru dan ahli-ahli part-time. Dan ahli2 baru juga
berpeluang mendapat bonus perkongsian sedunia – Power Pool dan
package percutian resort 5 bintang!
Terdapat ahli Winners4Life (Pak Yusuf/Kak Ramlah dari Kuala
Terengganu) yang meraih bonus lebih dari RM10,000 sebulan sejak dari
bulan pertama lagi! Rata-rata, ramai ahli-ahli baru, walaupun mereka yang
tidak mempunyai banyak pengalaman didalam bidang MLM, namun
mereka dapat meraih pendapatan RM1,000 – RM3,000 sebulan pada
peringkat awal lagi, dengan bimbingan dan sokongan kumpulan Winners.
Kini Winners telah melahirkan 6 ahli Presidential Diamond iaitu En Sadik
Din, Pak Yusuf/Pn Ramlah, Dr Hadifaar, Dr Tony Liew, En Akram Din
dan En Fadzli Salim. Tiada kumpulan lain di dalam syarikat ForLife
Research setakat ini, yang melahirkan Presidential Diamond Melayu Islam!
Alhamdulillah!! Winners Hebat! Winners Cemerlang! Winners Terus
Maju! Jutaan terima kasih untuk semua leader2 Winners yang luarbiasa
hebat! Salam hormat dari saya Sheri Din, International Diamond, Winners
4Life! –

• Allergi/ Alahan• Infeksi Liver• Arthritis• Step• Denggi• Vertigo• Autism• HIV• Migraine• Herpes• Campak• Gastrik• Batuk• Hepatitis• Infeksi Virus• Kanser/Tumor• Diabetes 1 & 2• Penyakit jantung• Darah tinggi• Penyakit² kulit• Buah pinggang• Asthma/ Semput• Alzheimer’s• Parkinson’s• Lupus/ SLE• Demam/ Flu• Gout/ Pirai• Tuberculosis (TB)• Resdung / Sinus.Bisa badan.Bird Flu.HFMD / SARS.Multiple Sclerosis.Parasitic diseases.Autoimmune diseases
Mycobacterial diseases.Fungal diseases.Malignant diseases Neurological diseases.Bacterial diseases
Bronchitis.Obesity/ Gemuk.Infeksi mata / rabun.Infeksi usus.Infeksi paru-paru

Berminat untuk mengetahui lebih lanjut peluang KESIHATAN DAN perniagaan 4life ??

HUBUNGI SAYA UNTUK MAKLUMAT LEBIH LANJUT DI= 0163153132(Zaidah)016-3143695 (AYIM)

July 20, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, malaysia | , | Leave a comment

BAGAIMANA MENGHINDARI PENYAKIT DAN MELAWAN PENYAKIT.

ASSALAMMULAIKUM DAN SELAMAT SEJAHTERA KEPADA SESIAPA YANG MENBACA BLOG SAYA.

PERTAMA SEKALI INGIN SAYA MEMPERKENALKAN TRANFER FACTOR 4LIFE UNTUK ANDA DAN KELUARGA ANDA DAN KEGUNAAN DALAM KEHIDUPAN ANDA SEKELUARGA DALAM MENCEGAH DAN MEMBANTU MELAWAN PENYAKIT.

RAMAI YANG SERING BERTANYA KEPADA SAYA APA ITU TRANSFER FACTOR DAN KEGUNAAN UNTUK DIRI MEREKA DALAM MELAWAN PENYAKIT DAN MENCEGAH PENYAKIT.

DISINI SAYA TERANGKAN SIKIT LEBIH KURANG BERKENAAN TRANSFER FACTOR.

1) TRANSFER FACTOR ADALAH MOLEKUL PENGETAHUAN TENTANG  PENYAKIT PENYAKIT.

2) TRANSFER FACTOR TIDAK MENGUBATI PENYAKIT TETAPI MENDORONG SISTEM PERTAHANAN BADAN KITA MELAWAN PENYAKIT DENGAN MEMBERI IMUN SISTEM KITA ILMU DAN GAMBARAN TENTANG PENYAKIT.

3)TRANSFER FACTOR BUKAN PRODUK YANG MEMPERKUATKAN TETAPI MEMPERPANDAIKAN IMUN SISTEM KITA DALAM MELAWAN PENYAKIT.

4) PRODUK TRANSFER FACTOR ADALAH PRODUCT YANG MEMPUNYAI HAK MILIK(PATENTED) OLEH SYARIKAT 4LIFE.JADI UNTUK MENCUBA PASTIKAN ANDA DAPAT DARI PENGEDAR 4LIFE YANG SAH.

5) TRANSFER FACTOR BUKAN VITAMIN/MINERAL/HERBA ATAU SEBARANG PRODUK YANG ANDA TEMUI DI PASARAN MALAYSIA,IA ADALAH KATEGORI YANG BARLAINAN DARI APA YANG ANDA KETAHUI.(clik sini untuk lebih tahu)

6) DENGAN TRANFER FACTOR ANDA MELINDUNGI DIRI ANDA DARI PELBAGAI PENYAKIT KERANA TRANSFER FACTOR ADALAH ILMU PENGETAHUAN YANG DI AMBIL DARI SUSU AWAL LEMBU DAN KUNIG TELOR AYAM.

BAYANG KAN SENARIO INI..

MANUSIA/AYAM/LEMBU MEMINUM AIR DI SAWAH PADI ATAU PARIT…

MANUSIA/AYAM/LEMBU DIHINGGAPI DI HURUNGI LALAT DI MULUT…

MANUSIA/AYAM/LEMBU BERDIRI MELEBIHI 12 JAM SEHARI…

KENAPA AYAM DAN LEMBU TIDAK MENGALAMI SAKIT PERUT ATAU LAIN LAIN PENYAKIT WALHAL MEREKA PUN MINUM/MELAKU PERBUATAN SEPERTI MANUSIA DALAM SENARIO DI ATAS??

JAWAPAN NYA MUDAH..

KERANA IMUN SISTEM AYAM DAN LEMBU PUNYAI PENGETAHUAN DAN MENGENALI LEBIH BANYAK KUMAN/VIRUS DAN SEL ROSAK DAN 4LIFE RESEARCH MEMPUNYAI PATENTED TERHADAP BAGAIMANA UNTUK MENGESTRAK TRANSFER FACTOR DARI AYAM DAN LEMBU BERKENAAN PENYAKIT DAN APABILA KITA MENGAMBIL TRANSFER FACTOR KITA MEMPUNYAI PERLINDUNGAN YANG LEBIH DALAM MELAWAN PENYAKIT ATAU MENGUBATI PENYAKIT KERANA IMUN SISTEM KITA LEBIH BERPENGETAHUAN.


KITA KALAH DALAM PERJUANGAN MELAWAN PENYAKIT BUKAN SEBAB KEKUATAN,TETAPI PENGETAHUAN.

DENGAN ILMU KITA BOLEH MENCEGAH PENYAKIT.

DENGAN ILMU KITA BOLEH MENGUBATI PENYAKIT.

DENGAN ILMU KITA BOLEH MENOLONG ORANG.

DENGAN ILMU KITA BOLEH MENYEDARKAN ORANG.


IBRAHIM WINNERS4LIFEMELAKA

0163581794/0163153132

June 20, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, malaysia, SAKIT, Uncategorized | , , , , , , , , , , , , , , , | Leave a comment

Follow

Get every new post delivered to your Inbox.